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Abstract: Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global health care
emergency. Anti-SARS-CoV-2 serological profiling of critically ill COVID-19 patients was performed
to determine their humoral response. Blood was collected from critically ill ICU patients, either
COVID-19 positive (+) or COVID-19 negative (−), to measure anti-SARS-CoV-2 immunoglobulins:
IgM; IgA; IgG; and Total Ig (combined IgM/IgA/IgG). Cohorts were similar, with the exception
that COVID-19+ patients had a greater body mass indexes, developed bilateral pneumonias more
frequently and suffered increased hypoxia when compared to COVID-19- patients (p < 0.05). The
mortality rate for COVID-19+ patients was 50%. COVID-19 status could be determined by antiSARS-CoV-2 serological responses with excellent classification accuracies on ICU day 1 (89%); ICU
day 3 (96%); and ICU days 7 and 10 (100%). The importance of each Ig isotype for determining
COVID-19 status on combined ICU days 1 and 3 was: Total Ig, 43%; IgM, 27%; IgA, 24% and IgG,
6%. Peak serological responses for each Ig isotype occurred on different ICU days (IgM day 13 >
IgA day 17 > IgG persistently increased), with the Total Ig peaking at approximately ICU day 18.
Those COVID-19+ patients who died had earlier or similar peaks in IgA and Total Ig in their ICU
stay when compared to patients who survived (p < 0.005). Critically ill COVID-19 patients exhibit
anti-SARS-CoV-2 serological responses, including those COVID-19 patients who ultimately died,
suggesting that blunted serological responses did not contribute to mortality. Serological profiling
of critically ill COVID-19 patients may aid disease surveillance, patient cohorting and help guide
antibody therapies such as convalescent plasma.
Keywords: COVID-19; intensive care unit; humoral response; serology; immunoglobulins; outcome
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distributed under the terms and
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1. Introduction
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2. Critically ill COVID19 patients are admitted to the intensive care unit (ICU), where the mortality rate is
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approximately 42% [1]. While a variety of patient risk factors have been identified, the
patient and infection attributes that contribute to ICU mortality are generally unknown.
Once infected, the body responds with the innate immune response [2,3]. An exaggerated
innate response has been suggested to underlie severe COVID-19 disease, referred to as
a ‘cytokine storm’, with evidence for increased interferons, TNF, bradykinin and serine
proteases [4–6]. Poorer outcomes have also been attributed to microvascular disease [7],
which is associated with microthrombi [8].
The innate reaction is followed by a humoral immune response, with production
of antigen-specific antibodies, or immunoglobulins (Ig) [9]. Five antibody isotypes are
named alphabetically based on their heavy chain class: alpha (IgA), delta (IgD), epsilon
(IgE), gamma (IgG), and mu (IgM). The intensity and duration of the SARS-CoV-2 humoral
response has been partially investigated [10,11], with studies demonstrating that the
response rate and the time to seroconversion are both variable depending on the targeted
antigen, the Ig isotype investigated, and the assay platform used [12]. The IgM response is
detected by 6–14 days after infection, while an IgG response begins shortly thereafter [13].
Serological studies in critically ill patients are few and limited by insufficient sampling
time points and/or focus on only one immunoglobulin isotype [14,15].
Serological profiling of critically ill COVID-19 patients over their ICU stay was the
overall aim of this study. Our specific objectives were: (1) to determine and compare
the serological responses between COVID-19-positive (+) ICU patients and either healthy
control subjects or COVID-19-negative (−) ICU patients; (2) to determine which Ig isotypes
dominate the serological responses in COVID-19+ patients; and (3) to determine whether
the serological responses differ between COVID-19+ patient outcome.
2. Results
We investigated and compared 4 age- and sex-matched populations: 14 critically
ill COVID-19+ patients (median years of age = 61.0, IQR = 54.0, 67.0), 14 critically ill
COVID-19- patients (median years of age = 58.5, IQR = 52.5, 63.0), 14 mildly ill nonhospitalized COVID-19+ patients (median years of age = 60.0, IQR = 55.8, 65.0), and
14 healthy controls (median years of age = 57.5, IQR = 53.3, 63.0; p = 0.645). Baseline
demographic characteristics, comorbidities, laboratory values, and chest x-ray results
are reported in Table 1. The COVID-19+ patients had a higher body mass index and
developed bilateral pneumonia more frequently, while COVID-19- patients were more
likely to suffer unilateral pneumonia. COVID-19+ patients had lower PaO2 :FiO2 ratios
when compared to COVID-19- patients, and were more likely to receive high-flow oxygen
therapy. Sepsis was ‘confirmed’ by infectious pathogen identification in only 28.6% of
COVID-19- patients, with sepsis ‘suspected’ in the remaining 71.4%. The mortality rate
was 50% for COVID-19+ patients.
Table 1. Demographics and clinical data for all age- and sex-matched study subjects.
Variable

COVID-19+
Critically Ill

COVID-19−
Critically Ill

COVID-19+
Mildly Ill

Healthy
Controls

n
Age in years
Sex
MODS
SOFA

14
61.0 (54.0, 67.0)
8F:6M
4.0 (3.0, 5.5)
4.5 (2.0, 9.3)

14
58.5 (52.5, 63.0)
8F:6M
6.0 (3.0, 8.0)
6.0 (4.3, 10.5)

14
60.0 (55.8, 65.0)
8F:6M

14
57.5 (53.3, 63.0)
8F:6M

Comorbidities, n(%)
Hypertension
Diabetes
Chronic kidney disease
Cancer
COPD
Heart disease
Chronic heart failure

7 (50.0)
5 (35.7)
2 (14.3)
2 (14.3)
1 (7.1)
2 (14.3)
0 (0)

9 (64.3)
5 (35.7)
1 (7.1)
1 (7.1)
3 (21.4)
2 (14.3)
2 (14.3)

p-Value
1.000
0.645
1.000
0.286
0.204
0.445
1.000
1.000
1.000
0.596
1.000
0.481
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Table 1. Cont.
COVID-19+
Critically Ill

COVID-19−
Critically Ill

Baseline labs
White blood count
Neutrophils
Lymphocytes
Platelets
Hemoglobin
Creatinine

8.5 (6.9, 16.1)
7.3 (5.6, 12.6)
0.7 (0.6, 1.0)
206 (134, 294)
122 (102, 135)
82 (58, 187)

15.3 (11.1, 20.5)
12.2 (8.6, 15.7)
1.3 (0.5, 1.8)
202 (164, 260)
124 (102, 138)
75 (54, 113)

0.056
0.062
0.093
0.872
0.818
0.448

Chest X-ray, n(%)
Bilateral pneumonia
Unilateral pneumonia
Interstitial infiltrates
Normal
PaO2 :FiO2 ratio
Lactate

13 (92.9)
1 (7.1)
0 (0)
0 (0)
107 (66, 162)
1.5 (1.0, 2.0)

2 (14.3)
8 (57.1)
1 (7.1)
3 (21.4)
172 (138, 312)
1.2 (0.9, 1.6)

<0.001
0.013
1.000
0.222
0.015
0.233

Sepsis diagnosis
Suspected
Confirmed

0 (0)
14 (100)

10 (71.4)
4 (28.6)

<0.001
<0.001

Study interventions
Antibiotics
Anti-virals
Steroids
Vasoactive medications
Renal replacement
High-flow nasal cannula
Non-invasive MV
Invasive MV ventilation
Survived

14 (100)
3 (21.4)
3 (21.4)
11 (78.6)
2 (14.3)
8 (57.1)
6 (42.9)
10 (71.4)
7 (50.0)

14 (100)
2 (14.3)
5 (35.7)
8 (57.1)
1 (7.1)
1 (7.1)
8 (57.1)
11 (78.6)
12 (85.7)

1.000
1.000
0.678
0.420
1.000
0.013
0.450
1.000
0.103

Variable

COVID-19+
Mildly Ill

Healthy
Controls

p-Value

Continuous data are presented as medians (IQRs). MODS = Multiple Organ Dysfunction Score, SOFA= Sequential Organ Failure Assessment
Score, COPD = Chronic Obstructive Pulmonary Disease, and MV = mechanical ventilation. Bold p-Values highlight statistical differences
between groups.

Serum levels of immunoglobulins (IgM, IgA, IgG and Total Ig) were measured using
previously validated immunoassays (Table 2), which performed well when compared
to other commercially available serology assays [16]. The only exception was the antiSARS-CoV-2 IgA ELISA that reported a positive percent agreement (PPA) of 85.7%, which
may reflect the brief period of IgA antibody prevalence that is highly variable between
individuals. Additionally, some individuals are IgA-deficient and therefore, IgA antibodies
are not produced upon a respiratory infection [17]. The precision of the immunoassays
used in the study was in line with the precision typically generated by ELISAs when all the
sources of variation are included in the analysis.
Table 2. Precision and clinical performance of anti-SARS-CoV-2 antibodies and immunoassays (Data provided by Diagnostics Biochem Canada Inc.; https://dbc-labs.com/; accessed on 13 May 2021).
Anti-SARS-CoV-2
IgM

Anti-SARS-CoV-2
IgA

* Anti-SARS-CoV-2
IgG

* Anti-SARS-CoV-2
Total Ig

Catalogue #

CAN-IGM-19

CAN-IGA-19

CAN-IGG-19

CAN-IGT-19

Total CV%

11.6–14.4

10.6–16.6

8.5–13.5

7.9–15.3

Sensitivity [PPA, % (n)]

93.5 (31)

85.7 (91)

93.1 (116)

94.7 (114)

Specificity [NPA, % (n)]

98.8 (781)

99.0 (789)

98.2 (677)

99.2 (783)

Overall Agreement [OPA, % (n)]

98.6 (812)

97.6 (880)

97.5 (793)

98.7 (897)

Limit of Detection

1:64

1:128

1:128

1:256
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Table 2. Cont.
Anti-SARS-CoV-2
IgM

Anti-SARS-CoV-2
IgA

* Anti-SARS-CoV-2
IgG

* Anti-SARS-CoV-2
Total Ig

ROC AUC (p < 0.0001)

0.987

0.993

0.992

0.988

ROC 95% Confidence Intervals

0.965, 1.009

0.988, 0.998

0.982, 1.002

0.973, 1.004

ROC Standard Error

0.0114

0.0026

0.0052

0.0078

* Health Canada COVID-19 Medical Device Authorized, CV% = Coefficient of Variation, PPA = positive percent agreement, NPA = negative
percent agreement, OPA = “overall percent agreement, ROC = receiver operating characteristic, and AUC = area under the curve.

Figure 1 shows four t-distributed stochastic neighbor embedding (t-SNE) plots corresponding to the combined antibody response on four separate ICU days (integration of
IgM, IgA and IgG). The combined antibody response can distinguish COVID-19+ versus
COVID-19- patients with increasing accuracy: ICU day-1, 89%; ICU day-3, 96%; ICU day-7,
100% and ICU day-10, 100%. Feature ranking provided the importance of each Ig assay for
determining COVID-19 status on combined ICU days-1 and -3 (Total Ig, 43%; IgM, 27%;
IgA, 24% and IgG, 6%).
Only 21% (n = 3/14) of critically ill COVID-19+ patients failed to exhibit a serological
response on ICU day-1; however, these 3 COVID-19+ patients developed Ig responses by
ICU day 3. In contrast, all COVID-19- patients (n = 14) fell below the established cut-off
values and, therefore, were considered serologically negative. All healthy control subjects
(n = 14) fell below the established cut-off values with the exception of one subject who
exhibited a weak IgM response, suggesting mild cross reactivity to another antigen in this
one healthy control subject (sample collected prior to November 2019).
We also compared the Ig responses between critically ill (ICU day-3 or near maximal
response) and mildly ill non-hospitalized COVID-19+ patients. Both cohorts displayed similar Ig responses despite differences in disease severity (all Ig comparisons non-significant;
Table 3).
Table 3. Anti-SARS-CoV-2 serological responses between age- and sex-matched COVID-19 patients
with either severe (ICU day-3) or mild (non-hospitalized) symptoms.
Variable

COVID-19+
Critically Ill

COVID-19+
Mildly Ill

p-Value

n
Age in years
Sex

14
61.0 (54.0, 67.0)
8F:6M

14
60.0 (55.8, 65.0)
8F:6M

1.000
0.711
1.000

Anti-SARS-CoV-2 Ig
IgM
IgA
IgG
Total Ig

2.8 (1.5, 5.3)
4.0 (1.5, 5.8)
8.1 (2.1, 14.5)
6.6 (3.7, 10.0)

2.8 (1.2, 3.3) *
2.0 (1.3, 6.5)
6.3 (2.5, 14.0)
6.8 (3.9, 9.6)

0.787
0.582
0.873
0.697

Continuous data are presented as medians (IQRs). * n = 13, with one patient value missing.

Figure 2 shows the Ig responses for all COVID-19 patients (n = 14). Each data set is
overlaid with a best fit curve. The peak responses for each antibody subgroup occurred
temporally in the following order: IgM on ICU day-13; IgA on ICU day-17; and IgG that
persistently increased. The peak response in the Total Ig occurred on approximately ICU
day 19.

Pathophysiology 2021, 28

Figure 1. T-distributed stochastic neighbor embedding (tSNE) plots comparing the integrated combined antibody
responses (IgM, IgA and IgG) between COVID-19+ and COVID-19- patients on different ICU days (the axes are
dimension-less). In all plots, subjects are indicated in two dimensions following a dimensionality reduction in their
respective antibody responses (the classification accuracy [CA] is indicated for each comparison). Green dots represent
COVID-19- patients, while red dots represent age- and sex-matched COVID-19+ patients. The clinical outcome for
all patients is shown as alive (circle) or dead (triangle). (A) ICU day-1; CA = 89%). The dimensionality reduction
shows some mixing of COVID-19+ patients with COVID-19- patients, suggesting that not all COVID-19+ patients have
developed a significant antibody response on ICU day-1. (B) The dimensionality reduction shows minimal mixing of
COVID-19+ patients with COVID-19- patients, suggesting that most COVID-19+ patients have developed a significant
antibody response by ICU day-3 (CA = 96%). (C,D) The dimensionality reduction shows that the two cohorts are distinct
and easily separable with all COVID-19+ patients having developed robust antibody responses by ICU days -7 and -10
(CA = 100%).
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Figure 2. Plots demonstrating Ig isotype responses in COVID-19+ patients over multiple ICU days. Four plots with a best-fit
line through the data points. Each Ig isotype has a unique time course peak: (A) IgM transiently peaking on or about ICU
day-13; (B) IgA transiently peaking on or about ICU day-17; and (C) IgG persistently increasing. (D) The total antibody
assay shows an Ig peak on approximately ICU day-19. The clinical outcome for all patients is shown as alive (blue circle) or
dead (red circle).

The Ig responses between COVID-19 patients that either survived to ICU discharge or
expired in the ICU were evaluated using two approaches. We first examined whether Ig
concentrations were different on ICU day-1 between critically ill COVID-19+ patients that
lived or died; there were no significant differences identified (IgM, p = 0.749; IgA, p = 0.277.
IgG, p = 0.522, Total Ig, p = 0.949). We then examined if Ig concentrations were different
in critically ill COVID-19+ patients that lived or died over their entire ICU stay. There
were significant interactions between days after ICU admission and COVID-19 patient
outcome (alive versus dead) for IgA (F(1,93) = 13.27, p < 0.001, η2 = 0.13) and for Total Ig
(F(1,93) = 9.20, p = 0.003, η2 = 0.09), indicating that patients who died had higher IgA and
Total Ig levels earlier in their ICU stay compared to patients who survived. In contrast,
there were no significant interactions between COVID-19 patient outcomes and either IgM
(p = 0.223) or IgG (p = 0.053).
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3. Discussion
In this study, we utilized 4 validated SARS-CoV-2 antibody immunoassays to measure
Ig isotypes in serum obtained from 4 age- and sex-matched populations: 14 critically ill
COVID-19+ patients, 14 critically ill COVID-19- patients, 14 mildly ill non-hospitalized
COVID-19+ patients, and 14 healthy controls. Given the number of Ig isotypes measured,
we analyzed the data with state-of-the-art machine learning, as well as conventional
statistics. Our data indicate the presence of a robust COVID-19 serological response that
was evident in all COVID-19 patients by ICU day-7. Moreover, the expected temporal
patterns were present for all individual Ig isotypes with peak responses occurring in
the following order: IgM on ICU day-13 > IgA on ICU day-17 > IgG that persistently
increased/plateaued. Finally, we determined that COVID-19 patients who died not only
had an equally robust serological response to those COVID-19 patients who survived, but
they also showed an earlier rise in IgA and Total Ig, the last likely due to the contribution of
IgA to the total antibody response. Our exploratory data suggest that critically ill COVID-19
patients develop robust serological responses that might not protect from poor outcome.
Our COVID-19+ ICU patients were comparable to those reported in other studies [18–21] with respect to demographic, comorbidities and clinical presentation. In contrast
to COVID-19- ICU patients, our COVID-19+ ICU patients developed bilateral pneumonia
more frequently and they had lower PaO2 /FiO2 ratios. A unique COVID-19 inflammatory
profile was previously characterized in many of these same patients and showed elevated
interferons, TNF and serine proteases [5,6], and a thrombotic profile associated with endothelial activation and glycocalyx degradation [7]. We also employed targeted proteomics
and metabolomics, thereby identifying novel biomarkers that accurately predict COVID-19
poor outcome [22,23]. Taken together, COVID-19 is a severe illness with a unique pathophysiological signature, as well as a high mortality rate. Despite standardized ICU care,
mortality in critically ill COVID-19 patients was 50%.
In all four SARS-CoV-2 Ig assays used here, a ROC analysis yielded an area under the
curve (AUC) higher than 0.987, indicating an outstanding discrimination between positive
and negative samples, a performance that persisted in studies including blood serum and
plasma specimens from nearly 300 individuals presenting an elevated titer of antibodies
against a broad spectrum of other infectious diseases (Table 2). In fact, the assays used
in this study performed well when compared to other commercially available serological
assays [16]. The viral S1 spike protein region used as antigen is currently a target of several
vaccines against SARS-CoV-2, which might potentially expand the applications of these
assays to measure vaccination seroconversion rates.
Our data showed that all critically ill COVID-19+ patients demonstrated a characteristic serological response on or before ICU day-7, as did all COVID-19+ subjects with mild
symptoms not requiring hospitalization. With regard to critically ill COVID-19+ patients,
the variability in antibody response may reflect the degree of viral load and/or delays
between infection and symptom onset requiring ICU admission. In contrast, none of the
age- and sex-matched COVID-19- ICU patients had a measurable serological response. In
the critically ill COVID-19+ patients, the temporal peak for each Ig isotype was as expected
for Ig isotypes [12,13], with approximate average peaks for IgM and IgA on ICU days-13
and -17, respectively. Serum IgG continued to increase to a steady state over the ICU course,
while Total Ig peaked on ICU day-19. Published data indicate a 38.3% antibody response
during the first 7 days of SARS-CoV-2 infection, and an 89.6% antibody response during
the second week of infection [11], consistent with the temporal course described in this
study. Others have demonstrated that 100% of COVID-19 patients expressed IgG by 17–19
days after onset of their symptoms [10].
The magnitude of SARS-CoV-2 antibody production after infection was similar between COVID-19 patients with variable disease severity, as we have also shown here,
before post-infectious day 12; however, antibody levels diverged to reflect disease severity
by 14 days after infection [11]. Our data demonstrate similar serological responses in
COVID-19 ICU patients who either died or survived. Moreover, those COVID-19 patients
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who died had a faster rate of rise in IgA and Total Ig. Taken together, our data suggest
that a blunted serological response does not contribute to COVID-19 mortality, and that
the faster antibody rise associated with COVID-19 mortality may reflect increased viral
load [24]. SARS-CoV-2 load was associated with both greater cytokine production and
lung injury [25], suggesting that cytokine modulators may be of therapeutic benefit, such
as TNF inhibitors [6].
Currently, there are no targeted therapies for COVID-19. Thus, there is interest
in human convalescent serum as a therapeutic option for prevention and treatment of
COVID-19 [26]. Ig containing serum requires sufficient numbers of people who have
recovered from COVID-19 and can donate blood. While historical evidence suggests that
IgG administration may prevent disease (i.e., respiratory syncytial virus), treatment of
active COVID-19 disease is controversial due to mixed results in clinical trials [27,28].
Given that the potential risks of convalescent serum administration include a transfusion
reaction and/or blunting of the endogenous humoral response, a personalized medicine
approach is warranted [29]. Indeed, profiling of anti-SARS-CoV-2 Ig (particularly IgG), as
we have done here, may be useful when combined with other clinical, genetic [30] and
lifestyle [31] factors to determine patient candidates that will benefit from this therapy.
Our serological profiling in critically ill COVID-19 patients was novel, but also had
several limitations. First, due to patient sampling methodologies we cannot determine the
disease onset or quantify symptom duration; however, ICU admission has strict criteria
for advanced monitoring or interventions and serves as a reasonable surrogate. Second,
while our study identified serological responses that failed to protect patients from a poor
outcome, our overall COVID-19 study population was limited in number and highlights
the need for larger cohort patient studies. Third, we report only mortality as our primary
clinical outcome. Fourth, due to the limited number of enrolled patients, our data must
be interpreted with caution. Future studies with larger sample sizes can explore whether
serological responses correlate with additional clinical outcomes such as functional status
in survivors. Finally, our analyses employed a cross-validation methodology, which is a
standard, accepted technique in machine learning, but should be validated on a larger
testing set that is used only once. Overfitting was minimized by using a very small number
of trees, and the very limited depth was protective against over-fitting [32].
4. Conclusions
In summary, we report serological responses in COVID-19 ICU patients, with expected temporal responses for individual Ig isotypes. While exploratory, our study filled a
knowledge gap on the intensity and pattern of humoral responses expressed by critically
ill COVID-19 patients. Given the rapid spread of COVID-19 and the critical need for therapies, our data may be important for refining future clinical trials with anti-SARS-CoV-2
antibody infusion.
5. Materials and Methods
5.1. Study Participants and Clinical Data
We enrolled consecutive patients who were admitted to our level-3 academic ICUs
at London Health Sciences Centre (London, ON, Canada) and were suspected of having
COVID-19 based on standard hospital screening procedures [33]. Blood sampling began
on ICU admission for up to 3 days in COVID-19- patients, or up to 7 days in COVID-19+
patients followed by every 3 days until death or discharge. COVID-19 status was confirmed
as part of standard hospital testing by detection of two SARS-CoV-2 viral genes using
polymerase chain reaction (Roche SARS-CoV-2 PCR kits, Roche Diagnostics, Rotkreuz,
Switzerland; FDA Authorized) [34]. Patient baseline characteristics were recorded on
ICU admission and interventions were documented [5–7,15,22,23]. Disease severity scores
were calculated [35,36]. Both patient groups were characterized as having confirmed or
suspected sepsis diagnosis using Sepsis 3.0 criteria [36]. For serological comparisons,
we included both non-hospitalized COVID-19+ patients with mild disease, and healthy
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control subjects who were public volunteers without disease, acute illness or prescription
medications (https://translationalresearchcentre.com/; accessed on 13 May 2021) [37,38].
Final participant groups were constructed by age and sex matching.
5.2. Blood Draws
Standard operating procedures were used to ensure all samples were treated rapidly
and equally [5–7,15,22,23,39]. Daily blood was obtained from critically ill ICU patients via
indwelling catheters using vacuum serum separator tubes and placed immediately on ice.
If a venipuncture was required, research blood draws were coordinated with a clinically
indicated blood draw. In keeping with accepted research phlebotomy protocols for adult
patients, blood draws did not exceed maximal volumes [40]. Once transferred to a negative
pressure hood, blood was centrifuged and sera isolated, aliquoted at 250 µL and frozen at
−80 ◦ C. All samples remained frozen until use and freeze/thaw cycles were avoided.
5.3. Immunoassays
Anti-SARS-CoV-2 antibodies (IgG, IgM, IgA, and Total Ig) were detected with four
separate enzyme-linked immunosorbent assays (ELISAs) kits developed at Diagnostics
Biochem Canada Inc. (https://dbc-labs.com/, accessed on 13 May 2021; London, ON,
Canada; Table 2). The antigen used in the anti-SARS-CoV-2 serology ELISA tests is a recombinant spike protein S1 subunit, RBD domain (aa 319–541). The “Total Ig” test kit detected
the sum of all three Ig isotypes (IgG, IgM and IgA). The tests were performed in accordance
with the ‘information for use’ (IFU) provided with each kit. Briefly, all four serological
tests were based on a sandwich immunoassay configuration. The antigen, coated to the
microplate wells, comprises one of the most specific protein regions of the SARS-CoV-2
virus enabling low cross-reactivity with other antibodies generated by numerous other
viruses, including other human coronaviruses. Anti-SARS-CoV-2 antibodies in serum that
bind to the antigen were detected with isotype-specific horse-radish peroxidase-conjugated
antibodies (for IgG, IgM and IgA tests) or with a mix for the Total Ig kit. Cut-off values
had been determined independently for each test during the design phase with a receiver
operating characteristic (ROC) analysis-based classification of samples previously known
to be SARS-CoV-2 positive or negative. The ratio between the serum sample optical density
(OD) and the OD of the negative control, adjusted with a calibration factor to match the
cut-off, was used to calculate the serum “ratio”. Sera with a ratio higher than the cut-off
were considered positive.
The immunoassay kit’s precision was evaluated according to the Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A3 (Table 2; provided by Diagnostics
Biochem Canada Inc, London, ON, Canada; https://dbc-labs.com/, accessed 13 May
2021). The clinical sensitivity of each immunoassay (positive percent agreement, PPA)
was validated with samples that tested positive for SARS-CoV-2 by PCR (for IgG and
the total antibodies ELISAs) or both for PCR and a prior immunoassay test (for IgA and
IgM ELISAs). The clinical specificity (negative percent agreement, NPA) was validated
against samples collected before the COVID-19 pandemic (November 2019) and, therefore,
considered SARS-CoV-2 negative. The overall percent agreement (OPA) was calculated as
the total number of times in which the immunoassays agreed with the pre-analytical status
of the specimen (positive or negative) divided by the total number of readings.
5.4. Population Statistics
Medians (IQRs) and frequency (%) were used to report ICU patient baseline characteristics for continuous and categorical variables, respectively; continuous variables were
compared using Mann–Whitney U tests (or Kruskal–Wallis tests, as appropriate), and
categorical variables were compared using Fisher’s exact chi-square. Linear, quadratic, or
logarithmic (as appropriate for best model fit) regression analyses were conducted separately for each antibody in order to examine the interaction between ICU days over time
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and those patients who lived or died. All population statistics were conducted using SPSS
version 26 (IBM Corp., Armonk, NY, USA). p-values < 0.05 were considered significant.
5.5. Machine Learning
COVID-19 analyte data were visualized with a non-linear dimensionality reduction on
the full data matrix using the t-distributed stochastic nearest neighbor embedding (t-SNE)
algorithm [41]. t-SNE attempts to find an optimal non-linear projection of the observed
data onto a manifold with complex geometry, but low dimension, embedded in the full
dimensional space of the raw data. A random forest classifier was also trained on the
variables to predict either COVID-19 status or COVID-19 outcome. A random forest is a
set of decision trees that can be interrogated to identify the features that have the highest
predictive value. To control overfitting, COVID-19 status was determined using a sevenfold cross validation with a random forest of ten trees with a max depth of three [32]. Data
from ICU day 3 COVID-19- patients were used as a proxy for day 7 and day 10 COVID-19patients when conducting the analysis.
Author Contributions: D.D.F. conceived the study, collected all biological samples, interpreted all
results and wrote the manuscript; G.C., E.K.P., D.B.O. and S.E.G. interpreted results and revised the
manuscript; M.S. and C.M.M. aided biological sample collection, interpreted results and revised
the manuscript; M.D., M.A.P. and M.R.M. performed machine learning and statistical analyses,
interpreted results and revised the manuscript; and I.H., J.P.P.J., C.M., L.N., X.W., J.Z., and J.A.C.-A.
performed immunoassays, interpreted results and revised the manuscript. All authors have read and
agreed to the published version of the manuscript.
Funding: D.D.F. received funding from Western University (Research), the Departments of Medicine and
Pediatrics at Western University, the Lawson Health Research Institute (https://www.lawsonresearch.
ca/), the London Health Sciences Foundation (https://lhsf.ca/), London Community Foundation and
the AMOSO Innovation Fund.
Institutional Review Board Statement: This study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review Board of Western University (REB
ID# 1670; issued 20 March 2020 and REB ID# 16986E; re-issued 10 March 2020).
Informed Consent Statement: This study was approved by the Western University, Human Research
Ethics Board (HREB). Given the unprecedented pandemic situation and the restricted hospital access
for substitute decision makers, waived consent was approved for a short, defined period of time
(6 months). In keeping with the Society for Critical Care Medicine statement on “Waiver of Informed
Consent in Emergency Situations”, the following criteria were considered relevant for HREB approval
of waived consent: the subjects were admitted to the ICU with a life-threatening condition; the
subjects had impaired decisional capacity; the research staff encountered significant obstacles and
delays when attempting to contact the absent substitute decision makers; the study risk was minimal;
the research knowledge gained on this new, lethal disease offered an eventual chance of benefit; and
community consultation had been implemented. Given the pandemic circumstances and the waived
consent model applied, no further attempts were made to contact the surviving patients and/or
substitute decision makers. The last patient enrolled under waived consent was 1 May 2020.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: We thank the entire Lawson COVID-19 Study Team for their assistance (Robert
Arntfield, Ian Ball, Gordon Barkwell, Tracey Bentall, Karen Bosma, Saoirse Cameron, Eileen Campbell,
David Carter, Carolina Gillio-Meina, Robert Hegele, Natalya Odoardi, Ram Singh, Shannon Seney,
Kelly Summers and Sue Tereschyn). We are grateful for the enthusiastic support of the frontline
Critical Care Nursing Staff at London Health Sciences Centre.
Conflicts of Interest: Some authors are employees of Diagnostics Biochem Canada (DBC) who
manufacture and distribute the anti-SARS-CoV-2 immunoglobulin assays.

Pathophysiology 2021, 28

222

References
1.
2.
3.
4.

5.

6.

7.

8.

9.
10.
11.
12.
13.
14.
15.

16.
17.
18.

19.

20.

21.

22.

23.

24.

Armstrong, R.A.; Kane, A.D.; Cook, T.M. Outcomes from intensive care in patients with COVID-19: A systematic review and
meta-analysis of observational studies. Anaesthesia 2020, 75, 1340–1349. [CrossRef] [PubMed]
Koyama, S.; Ishii, K.J.; Coban, C.; Akira, S. Innate immune response to viral infection. Cytokine 2008, 43, 336–341. [CrossRef]
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